Spruce Biosciences IncNASDAQ:SPRBNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5461
- TODAY'S CHANGE (%)0.0013 (0.2386%)
- Bid / Lots0.5401/ 10
- Ask / Lots0.5449/ 4
- Open / Previous Close0.5442 / 0.5448
- Day Range
- 52 Week Range
- Volume117,589
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SPRB |
|---|---|---|
| 09:32 ET | 150 | 0.5442 |
| 09:36 ET | 2123 | 0.5437 |
| 09:38 ET | 500 | 0.5437 |
| 09:41 ET | 500 | 0.5439 |
| 09:45 ET | 1243 | 0.546 |
| 09:48 ET | 19861 | 0.5494 |
| 09:50 ET | 10990 | 0.5501 |
| 09:52 ET | 100 | 0.5502 |
| 09:54 ET | 3200 | 0.5501 |
| 09:57 ET | 200 | 0.544 |
| 09:59 ET | 1100 | 0.544 |
| 10:06 ET | 1000 | 0.5467 |
| 10:10 ET | 643 | 0.54525 |
| 10:12 ET | 100 | 0.544 |
| 10:24 ET | 606 | 0.545 |
| 10:32 ET | 2280 | 0.5431 |
| 10:44 ET | 350 | 0.5432 |
| 10:46 ET | 600 | 0.5432 |
| 10:51 ET | 100 | 0.5432 |
| 11:00 ET | 300 | 0.5431 |
| 11:06 ET | 206 | 0.5431 |
| 11:15 ET | 1109 | 0.5423 |
| 11:22 ET | 7552 | 0.5422 |
| 11:24 ET | 450 | 0.5426 |
| 11:26 ET | 300 | 0.543 |
| 11:31 ET | 285 | 0.5422 |
| 11:33 ET | 269 | 0.5422 |
| 11:38 ET | 1362 | 0.5422 |
| 11:42 ET | 200 | 0.5423 |
| 11:49 ET | 3954 | 0.5401 |
| 12:12 ET | 1634 | 0.5404 |
| 12:25 ET | 100 | 0.5426 |
| 12:27 ET | 200 | 0.5426 |
| 12:30 ET | 100 | 0.5404 |
| 01:08 ET | 3140 | 0.541 |
| 01:15 ET | 690 | 0.541 |
| 01:21 ET | 3461 | 0.5421 |
| 01:24 ET | 198 | 0.543 |
| 01:44 ET | 200 | 0.543 |
| 01:55 ET | 400 | 0.5449 |
| 01:57 ET | 936 | 0.5433 |
| 02:13 ET | 500 | 0.5473 |
| 02:15 ET | 500 | 0.5473 |
| 02:18 ET | 715 | 0.5474 |
| 02:44 ET | 200 | 0.5488 |
| 02:47 ET | 100 | 0.5488 |
| 02:51 ET | 505 | 0.549 |
| 03:00 ET | 300 | 0.5492 |
| 03:05 ET | 7400 | 0.547 |
| 03:07 ET | 610 | 0.5451 |
| 03:16 ET | 100 | 0.5451 |
| 03:39 ET | 493 | 0.5453 |
| 03:41 ET | 352 | 0.5457 |
| 03:45 ET | 850 | 0.5451 |
| 03:54 ET | 100 | 0.5456 |
| 03:56 ET | 10197 | 0.5474 |
| 03:57 ET | 400 | 0.5451 |
| 03:59 ET | 6800 | 0.5461 |
Today
Yesterday
Investors With Losses Encouraged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm, from 4:02PM ET on Thursday Jul 25, 2024 by Dow Jones
4:02PM ET on Thursday Jul 25, 2024 by Dow Jones
Jul 23, 2024
Investors With Losses Encouraged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm, from 7:01PM ET on Tuesday Jul 23, 2024 by Dow Jones
7:01PM ET on Tuesday Jul 23, 2024 by Dow JonesInvestors With Losses Encouraged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm, from 2:05PM ET on Tuesday Jul 23, 2024 by Dow Jones
2:05PM ET on Tuesday Jul 23, 2024 by Dow Jones
Jul 19, 2024
The Schall Law Firm Is Investigating Spruce Biosciences Incorporated And Encourages Investors With Losses To Initiate Dialogue, from 4:45PM ET on Friday Jul 19, 2024 by Dow Jones
4:45PM ET on Friday Jul 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Spruce Biosciences Inc | 22.4M | -0.5x | --- |
Aspira Women's Health Inc | 18.7M | -1.1x | --- |
Curis Inc | 35.5M | -0.7x | --- |
BioNexus Gene Lab Corp | 8.9M | -3.5x | --- |
VBI Vaccines Inc | 15.5M | -0.1x | --- |
Jaguar Health Inc | 7.7M | 0.0x | --- |
Company Information
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.
Contact Information
- Headquarters
- 611 Gateway Boulevard, Suite 740SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 415-655-4168
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board
- Michael Grey
- President, Chief Financial Officer
- Samir Gharib
- Chief Executive Officer, Director
- Javier Szwarcberg
- Chief Medical Officer
- Ralph Charlton
- Independent Director
- Tiba Aynechi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $22.4M |
|---|---|
Revenue (TTM) | $10.1M |
Shares Outstanding | 41.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.39 |
EPS | $-1.15 |
Book Value | $1.86 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 2.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -507.82% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
